MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced that its research and diagnostic antibodies unit AbD Serotec has signed a license agreement with The Institute of Cancer Research (ICR), London, which provides AbD Serotec with worldwide exclusive rights to commercialize the...